Bouguerne, B., Belkheiri, N., Bedos-Belval, F., Vindis, C., Uchida, K., Duran, H., Grazide, M.H., Baltas, M., Salvayre, R. and Nègre-Salvayre, A. (2011) Antiatherogenic Effect of Bisvanillyl-Hydrazone, a New Hydralazine Derivative with Antioxidant, Carbonyl Scavenger, and Antiapoptotic Properties. Antioxidant and Redox Signaling, 14, 2093-2106.
http://dx.doi.org/10.1089/ars.2010.3321

has been cited by the following article:

• TITLE: Synthesis, Molecular Structure and Anti-Onchocercal Studies of 1-(Phthalazin-1(2H)-one)[(Pyridin-2-yl)ethylidene]hydrazone

  AUTHORS: Joseph N. Yong, Felicite Majoumo-Mbe, Moses Samje, Emmanuel N. Nfor

  KEYWORDS: Hydralazine Hydrochloride, Schiff Bases, Anti-Onchocercal Activity

  JOURNAL NAME: International Journal of Organic Chemistry, Vol.6 No.1, March 30, 2016

  ABSTRACT: The novel ligand, 1-(phthalazin-1(2H)-one)[(pyridin-2-yl)ethylidene]hydrazone,(APN), derived from the antihypertensive drug, hydralazine hydrochloride, was synthesized and characterized by spectroscopic methods (IR, 1H NMR). The X-ray crystallographic data indicates that APN has an exocyclic C=N bond on the hydralazine moiety. APN revealed significant anti-onchocercal activity with IC50 values of 0.3125 μg/mL on microfilaria and 10 μg/mL on adult worms compared to the standard drug, ivermectin.